NEW YORK (GenomeWeb News) – Becton Dickinson has exclusive rights to negotiate an acquisition of TriPath Imaging, according to documents filed with the Securities and Exchange Commission yesterday.
 
As GenomeWeb News reported on Tuesday, Becton Dickinson offered  buy all outstanding TriPath shares for $9.25 each, or about $350 million. The company currently holds a 6.5-percent stake in TriPath.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.